Form 4: Imunon Director Braun Acquires Shares

Donald P. Braun, a Director at Imunon, Inc., acquired 5,011 shares of common stock on May 22, 2026, as compensation for board fees.

Summary

• Donald P. Braun, a Director of Imunon, Inc., acquired 5,011 shares of common stock on May 22, 2026.
• The acquisition was made in lieu of cash for a portion of his board fees.
• The purchase price was $2.20 per share, totaling $11,024.20.
• Following this transaction, Mr. Braun beneficially owns 9,319 shares of common stock.
• A stock dividend of 15% was paid on August 21, 2025, which adjusted previously reported share amounts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a routine director stock acquisition for compensation rather than significant financial or strategic news.

Positives

• Director compensation in the form of stock aligns management interests with shareholders.
• The acquisition of shares by a director indicates confidence in the company's future prospects.
• The transaction was executed at a specific price, providing transparency.

Negatives

• The filing does not provide details on the company's financial performance or strategic direction, making it difficult to assess the broader implications of this transaction.

Risks

• The filing does not explicitly mention any risks associated with this transaction or the company's operations.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• Stock granted in lieu of cash for portion of board fees.
• The Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025.
• As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

Industry Context

StockSavvy.ai notes that the use of stock grants for director compensation is a common practice across the biotechnology and pharmaceutical industries, aiming to align executive incentives with long-term shareholder value creation. However, without further context on Imunon's specific financial health or pipeline progress, it's difficult to assess the significance of this particular grant relative to industry peers.

Related Party Transactions

• Donald P. Braun, a Director, acquired 5,011 shares of common stock as compensation for board fees.

Stakeholder Impact

• Shareholders: The issuance of stock for director fees dilutes existing shareholders' ownership slightly, but also aligns director incentives with shareholder interests.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• No specific next steps are mentioned in relation to this transaction.

Key Dates

Keywords

Imunon, IMNN, Form 4, SEC Filing, Insider Trading, Director Compensation, Common Stock, Share Acquisition